Abstract library

577 results for "somatostatin receptor-specific monoclonal antibodies".
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#2853 Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry
Introduction: The established category of succinate dehydrogenase (SDH) deficient neoplasms includes several endocrine tumours with recent evidence that pancreatic neuroendocrine tumours (PNETs) could be included in this tumour group. The SDH complex is composed of four subunits (A-D) but loss of immunohistochemical (IHC) expression for SDHB indicates bi-allelic inactivation of any SDH component and is used as a marker for syndromic disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr. Niall Swan
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#143 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig
#183 Immunhistochemical Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors Using IRS- and Her2-scoring Scheme
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are known for an overexpression of somatostatin receptors (SSTR). This finding has already gained importance in diagnostics and therapy of NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Luisa Peter
Authors: Peter L, Kaemmerer D, Lupp A, Saenger J, ...
#195 UMB-4 as New Monoclonal Somatostatin Receptor Antibody: Correlation of Immunostaining with Molecular Imaging using Somatostatin Receptor PET/CT
Introduction: Somatostatin receptors (SSTR) are known for an overexpression in neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Peter L, Lupp A, Schulz S, ...
#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies
Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Herbert Schmid
#657 Correlation of Monoclonal and Polyclonal Somatostatin Receptor (SSTR) 5 Antibodies in Pancreatic Neuroendocrine Tumors
Introduction: For a few years now, highly specific monoclonal antibodies have been available to characterize neuroendocrine tumors for somatostatin-receptor (SSTR) expression.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Authors: Kaemmerer D, Lupp A, Peter L, Fischer E, ...
#689 Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors
Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD Larisa Gurevich
#1038 Co-Expression of Somatostatin and CXCR4 Receptors as Targets for Diagnostics and Treatment in Intestinal Neuroendocrine Neoplasms.
Introduction: Somatostatin receptors (SSTR) are widely distributed in well-differentiated neuroendocrine tumors (NET) and serve as primary targets for diagnostics and treatment. An overexpression of the chemokine receptor CXCR4, in contrast, is considered to be present mainly in highly proliferative and advanced carcinomas.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Daniel Kaemmerer
Keywords: sstr